Top Page
Oxford Nanopore Technologies PLC
(LSE:ONT)
Oxford Nanopore Technologies PLC (ONT) vs. iShares MSCI United Kingdom ETF (EWC)
Oxford Nanopore Technologies PLC Business Overview & Revenue Model
Oxford Nanopore Technologies PLC Earnings Call Summary
Oxford Nanopore Technologies PLC Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 183.19M | 169.67M | 198.60M | 133.66M | 113.86M |
| Gross Profit | 105.39M | 90.48M | 123.81M | 73.19M | 46.88M |
| EBITDA | -93.09M | -105.71M | -49.67M | -140.34M | -55.07M |
| Net Income | -146.19M | -154.51M | -91.03M | -167.61M | -61.24M |
Balance Sheet | |||||
| Total Assets | 742.05M | 777.06M | 823.89M | 841.87M | 281.21M |
| Cash, Cash Equivalents and Short-Term Investments | 338.37M | 270.05M | 476.19M | 618.47M | 80.86M |
| Total Debt | 45.96M | 41.66M | 34.10M | 24.80M | 23.63M |
| Total Liabilities | 155.71M | 133.21M | 130.33M | 137.89M | 95.28M |
| Stockholders Equity | 586.34M | 643.85M | 693.56M | 703.98M | 185.93M |
Cash Flow | |||||
| Free Cash Flow | -123.83M | -164.59M | -91.62M | -84.64M | -90.28M |
| Operating Cash Flow | -109.89M | -137.30M | -49.39M | -53.83M | -63.81M |
| Investing Cash Flow | 15.03M | -61.79M | -65.79M | -161.99M | -26.94M |
| Financing Cash Flow | 73.58M | 64.73M | -13.71M | 622.90M | 158.58M |
Oxford Nanopore Technologies PLC Technical Analysis
Oxford Nanopore Technologies PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | £1.36B | ― | -23.77% | ― | 7.97% | 12.94% | |
56 Neutral | $339.64M | ― | -66.23% | ― | 43.84% | 74.88% | |
55 Neutral | £304.64M | 7.90 | 11.74% | ― | 38.80% | ― | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
46 Neutral | £98.49M | ― | 167.16% | ― | -100.00% | -23.91% | |
39 Underperform | £117.97M | ― | -73.02% | ― | ― | ― |
Oxford Nanopore Technologies PLC Corporate Events
Oxford Nanopore Technologies PLC announced the issuance of 69,871 ordinary shares following the exercise of options under its share option plans and remuneration schemes. These shares have been admitted to the London Stock Exchange, increasing the company’s issued share capital to 961,064,991 ordinary shares, which impacts the total voting rights and shareholder calculations under FCA rules.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £250.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC has announced a change in the voting rights held by EIT Oxford Holdings, LLC, which has increased its stake to 16.09% from a previous 15.09%. This acquisition of voting rights signifies a notable shift in shareholder influence, potentially impacting the company’s strategic decisions and governance. The change reflects ongoing interest and investment in the company’s innovative sequencing technology, which may influence its market positioning and stakeholder confidence.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC has announced a change in major holdings, with EIT Oxford Holdings, LLC increasing its voting rights from 14.046% to 15.095%. This adjustment in shareholder voting rights reflects a strategic move that could influence the company’s governance and decision-making processes, potentially impacting its market strategy and stakeholder interests.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC announced a transaction involving its Share Incentive Plan (SIP), where 119 ordinary shares were awarded to Nick Keher, the Chief Financial Officer, as part of his participation in the plan. The transaction, conducted through the SIP Trustee, reflects the company’s commitment to aligning managerial interests with shareholder value, potentially enhancing stakeholder confidence in the company’s governance practices.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC has announced a change in the voting rights held by Baillie Gifford & Co, a major stakeholder. The voting rights have decreased from 5.04% to 4.97%, reflecting a slight reduction in Baillie Gifford’s stake in the company. This adjustment in holdings may influence the company’s shareholder dynamics and could have implications for its governance and strategic decision-making.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies plc held its Annual General Meeting, where all proposed resolutions were passed with the required majority. The meeting included the approval of financial reports, director elections, and auditor appointments. Notably, Resolution 12 faced significant opposition, with over 20% of votes against it, prompting the Board to commit to further engagement with shareholders to address concerns. This outcome highlights the company’s ongoing efforts to maintain transparent communication with stakeholders and adapt to shareholder feedback.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £250.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC announced the issuance of 540,197 ordinary shares following the exercise of options under its share option plans and remuneration schemes. These shares have been admitted to the London Stock Exchange’s main market, increasing the company’s total voting rights to 960,995,120. This development reflects the company’s ongoing efforts to enhance its equity base and maintain transparency in its shareholder communications.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC has announced a change in its major holdings, with EIT Oxford Holdings, LLC increasing its voting rights from 13.0576% to 14.046%. This adjustment reflects a strategic move by EIT Oxford Holdings, LLC, a company controlled by Lawrence J. Ellison, indicating increased confidence and investment in Oxford Nanopore’s future prospects. The change in holdings may influence the company’s strategic direction and impact its market positioning, potentially affecting stakeholders and investors.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies plc presented significant updates at their annual London Calling conference, showcasing advancements in their molecular sensing platform. Key updates include enhancements in product performance, analytics, and direct RNA sequencing, as well as a focus on regulated product pipelines and proteomics. These developments aim to improve the company’s competitive edge and expand its applications in biopharma and clinical markets, potentially impacting stakeholders by broadening the scope of molecular analysis and increasing adoption in applied markets.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies plc has announced a transaction involving the Share Incentive Plan (SIP), where 112 ordinary shares were awarded to Nick Keher, the Chief Financial Officer, as part of a purchase using his gross salary. The company also issued 112 matching shares to the SIP Trustee to satisfy the award under the SIP. This move is part of the company’s compliance with the UK Market Abuse Regulation, reflecting its commitment to transparent managerial practices and aligning employee incentives with company performance.
The most recent analyst rating on (GB:ONT) stock is a Buy with a £260.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.
Oxford Nanopore Technologies PLC announced the issuance of 5,007,671 ordinary shares following the exercise of options and remuneration schemes, which are now listed on the London Stock Exchange. This increases the company’s total voting rights to 960,454,923, providing a new denominator for shareholders to calculate their interests in accordance with FCA rules.
Oxford Nanopore Technologies PLC announced the release of 42,953 ordinary shares under its Long-Term Incentive Plan (LTIP) to CEO Gordon Sanghera. This release, part of a performance-related award granted in 2021, required Sanghera to sell a portion of the shares to meet tax obligations, with the remaining shares retained. The transaction, conducted on the London Stock Exchange, highlights the company’s ongoing commitment to rewarding its leadership while maintaining transparency in its executive compensation practices.
Oxford Nanopore Technologies plc has released its 2024 Annual Report and Accounts and announced its 2025 Annual General Meeting. The company encourages shareholders to participate in the AGM, which will be held on June 4, 2025, at their Oxford offices. This announcement is part of their compliance with regulatory requirements and provides shareholders with insights into the company’s financial status and governance.
Oxford Nanopore Technologies PLC has announced a change in the voting rights held by EIT Oxford Holdings, LLC, which has increased its stake to 13.0576% from a previous 12.1864%. This change signifies a notable shift in shareholder structure, potentially impacting the company’s governance and strategic decisions, as EIT Oxford Holdings, LLC, linked to Lawrence J. Ellison, now holds a significant portion of voting rights.
Oxford Nanopore Technologies PLC announced the grant and vesting of awards under its Long Term Incentive Plan (LTIP) and Deferred Bonus Plan (DBP) for its directors. The awards, which are part of the company’s employee share plans, are designed to align the interests of management with shareholders and are contingent upon meeting specific performance conditions. This strategic move underscores the company’s commitment to incentivizing its leadership team, potentially enhancing its competitive positioning in the biotechnology sector.
Oxford Nanopore Technologies PLC announced a transaction involving its Share Incentive Plan (SIP) where Nick Keher, the company’s Chief Financial Officer, was awarded 129 Partnership Shares. These shares were purchased using his gross salary at a price of £1.16 per share. Additionally, the company issued 129 Matching Shares to the SIP Trustee to hold on behalf of Keher, reflecting the company’s commitment to employee investment and retention strategies. This move underscores the company’s adherence to UK Market Abuse Regulation and highlights its efforts to align managerial interests with shareholder value.
Oxford Nanopore Technologies PLC has announced a change in the voting rights held by EIT Oxford Holdings, LLC, which now holds 12.1864% of the company’s voting rights, up from 11.0673%. This increase in voting rights signifies a notable shift in shareholder influence, potentially impacting the company’s strategic decisions and stakeholder dynamics.
Oxford Nanopore Technologies and Cepheid have announced a strategic collaboration to create an automated sequencing workflow for infectious diseases. This partnership aims to simplify and accelerate sequencing processes, making them accessible to labs without prior expertise, and has potential applications in other areas like cancer and human genetics.